

Exhibit 2190
Corrected Exhibit 2157
Materials Considered by Dr. Michael A. Gorin, M.D.

Exhibit No.	Description
Paper 2	Petition for Inter Partes Review filed September 26, 2025
Paper 14	Patent Owner's Preliminary Response filed April 3, 2026
1001	U.S. Patent No. 10,980,901 ("the '901 patent")
1002	Declaration of Dr. Michael Zalutsky, and cited references (Exhibits 1001, 1004-1044)
1003	Curriculum Vitae of Dr. Michael Zalutsky, Ph.D.
1004	File History of U.S. Patent No. 10,980,901
1005	Marc A. Bjurlin, et al., <i>Imaging and evaluation of patients with high-risk prostate cancer</i> , 12 Nature Reviews Urology 617 (2015) ("Bjurlin").
1006	Kristell Chatalic, et al., <i>²¹³Bi-labeled PSMA-targeting agents for alpha radionuclide therapy of prostate cancer</i> , 57 J. Nuclear Med. 137 (2016) ("Chatalic").
1007	Emre Demirci, <i>⁶⁸Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma</i> , 41 Eur. J. Nuclear Med. Molecular Imaging 1461 (2014) ("Demirci").
1008	Catherine A. Foss, et al., <i>Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer</i> , 11 Clinical Cancer Rsch. 4022 (2005) ("Foss").
1009	Shawn Hillier, et al., <i>[¹³¹I] MIP-1375, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted therapy of prostate cancer (PCa)</i> , 52 J. Nuclear Med. 361 (2011) ("Hillier 2011").

Exhibit No.	Description
1010	Shawn Hillier, et al., [^{131}I] MIP-1466, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted radiotherapy of prostate cancer (PCa), 53 J. Nuclear Med. 170 (2012) (“Hillier 2012”).
1011	Joseph G. Jurcic, et. al., <i>Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (^{225}Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older</i>
1012	Susan J. Mandel, et al., <i>Superiority of Iodine-123 Compared with Iodine-131 Scanning for Thyroid Remnants in Patients with Differentiated Thyroid Cancer</i> , 26 Clinical Nuclear Med. 6 (2001) (“Mandel”).
1013	Michael R. McDevitt, et al., <i>Tumor Therapy with Targeted Atomic Nanogenerators</i> , 294 Science 1537 (2001) (“McDevitt 2001”).
1014	Michael R. McDevitt, et al., <i>Design and synthesis of ^{225}Ac radioimmunopharmaceuticals</i> , 57 Applied Radiation & Isotopes 841 (2002) (“McDevitt 2002”).
1015	Matthias Miederer, et al., <i>Preclinical Evaluation of the α-Particle Generator Nuclide ^{225}Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors</i> , 14 Clinical Cancer Rsch. 3555 (2008) (“Miederer 2008a”).
1016	Dianne E. Milenic & Martin W. Brechbiel, <i>Targeting of Radio-Isotopes for Cancer Therapy</i> , 3 Cancer Biology & Therapy 361 (2004) (“Milenic”).
1017	George Sgourous, et al., <i>MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy</i> , 51 J. Nuclear Med. 311 (2010) (“MIRD Pamphlet”).
1018	Natsuko Normura, et al., <i>Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases</i> , 14 Cancer Cell Int'l 1 (2014) (“Nomura”).
1019	Martin G. Pomper, et al., <i>^{11}C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase)</i> , 1 Molecular Imaging 96 (2002) (“Pomper”).

Exhibit No.	Description
1020	Justin R. Hubenak, et al., <i>Mechanisms of injury to normal tissue after radiotherapy: a review</i> , 133 Plastic Reconstructive Surgery 49 (2014) (“Hubenak”).
1021	Jeffery S. Ross, et al., <i>Correlation of Primary Tumor Prostate-Specific Membrane Antigen Expression with Disease Recurrence in Prostate Cancer</i> , 9 Clinical Cancer Rsch. 6357 (2003) (“Ross”).
1022	David A. Scheinberg & Michael R. McDevitt, <i>Actinium-225 in targeted alpha-particle therapeutic applications</i> , 4 Current Radiopharmaceuticals 306 (2011) (“Scheinberg”).
1023	David A. Silver, et al., <i>Prostate-specific Membrane Antigen Expression in Normal and Malignant Human Tissues</i> , 3 Clinical Cancer Rsch. 81 (1997) (“Silver”).
1024	Baris Turkbey, et al., <i>Multiparametric Prostate Magnetic Resonance Imaging in the Evaluation of Prostate Cancer</i> , 66 CA: Cancer J. for Clinicians 326 (2016) (“Turkbey”).
1025	U.S. Patent No. 10,471,160 (“the ‘160 patent”).
1026	U.S. Patent No. 10,398,791 (“the ‘791 patent”).
1027	Martina Weineisen, et al., <i>Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer</i> , 4 EJNMMI Rsch. 1 (2014) (“Weineisen 2014”).
1028	Martina Weineisen, et al., <i>⁶⁸Ga-and ¹⁷⁷Lu-labeled PSMA I&T. Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies</i> , 56 J. Nuclear Med. 1169 (2015) (“Weineisen 2015”).
1029	Alla G. Wernicke, et al., <i>Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers</i> , 122 APMIS 482 (2014) (“Wernicke”).
1030	Matthias Miederer, et al., <i>Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications</i> , 60 Advanced Drug Delivery Revs. 1371 (2008) (“Miederer 2008b”).

Exhibit No.	Description
1031	Clemens Kratochwil, et al., <i>Ac-225-DOTATOC - an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors</i> , 56 J. Nuclear Med. 1232 (2015) (“Kratochwil”).
1032	Randall D. Knight, <i>Physics For Scientists and Engineers</i> 1369–70 (Adam Black et al. eds., vol. 5 2005) (“Knight”).
1033	Liang Zhao, et al., <i>Clinical pharmacology considerations in biologics development</i> , 33 Acta Pharmacologica Sinica 1339 (2012) (“Zhao”).
1034	U.S. Dep’t Health & Hum. Servs., <i>Anthropometric Reference Data for Children and Adults: United States, 2015–2018 Series 3</i> , 9 (2021) (“HHS”).
1035	Nerissa Viola-Villegas & Robert P. Doyle, <i>The coordination chemistry of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (H4DOTA): Structural overview and analyses on structure–stability relationships</i> , 253 Coordination Chemistry Reviews 1906 (2009) (“Viola-Villegas”).
1036	Nima Sharifi, et al., <i>Androgen Deprivation Therapy for Prostate Cancer</i> , 294 JAMA 238 (2005) (“Sharifi”).
1037	Nat’l Cancer Inst., <i>SEER Cancer Stat Facts: Prostate Cancer</i> , seer.cancer.gov, https://seer.cancer.gov/statfacts/html/prost.html (last visited Jan. 31, 2023) (“NCI”).
1038	Sharmila Banerjee, et al., <i>Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications</i> , 115 Chem. Revs. 2934 (2015) (“Banerjee”).
1039	Arundhati Ghosh & Warren D.W. Heston, <i>Tumor Target Prostate Specific Membrane Antigen (PSMA) and its Regulation in Prostate Cancer</i> , 91 J. Cellular Biochemistry 528 (2004) (“Ghosh”).
1040	Declaration of Dr. Rebecca Abergel, Ph.D.
1041	Eric W. Price and Chris Orvig, <i>Matching chelators to radiometals for radiopharmaceuticals</i> , 43 Chem. Soc. Rev. 260-290 (2014) (“Price”).

Exhibit No.	Description
1042	Kristell L.S. Chatalic, et al., <i>Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent</i> , 6(6) <i>Theranostics</i> , 849-861 (2016) (“Chatalic 2016b”)
1043	Robin M. de Kruijff, et al., <i>A Critical Review of Alpha Radionuclide Therapy – How to Deal with Recoiling Daughters?</i> , 8 <i>Pharmaceuticals</i> , 321-336 (2015) (“de Kruijff”)
1044	Declaration of Dr. Thomas Hope, M.D.
1045	Kratochwil et al., “225 Ac-PSMA-617 for PSMA-Targeted α -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer,” <i>Journal of Nuclear Medicine</i> , vol. 57, no. 12, pgs. 1941-1944 (2016) (Kratochwil 2016)
1046	Xofigo® FDA label packaging insert (revised May 2013)
2070	Center MM, et al., International variation in prostate cancer incidence and mortality rates. <i>Eur Urol.</i> 2012;61(6):1079–92
2071	Bidkar, AP, et al., Actinium-225 targeted alpha particle therapy for prostate cancer, <i>Theranostics</i> 2024 14(7):2969-2992.
2072	Miederer, M, et al., Pharmacokinetics, Dosimetry, and Toxicity of the Targetable Atomic Generator, 225Ac-HuM195, in Nonhuman Primates, <i>J Nucl. Med.</i> 2004; 45:129–137
2074	The Journal of Nuclear Medicine, About the Cover, December 1, 2016, Vol. 57, Issue 12, https://jnm.snmjournals.org/content/57/12.cover-expansion (last visited November 21, 2023)
2075	U.S. Patent No. 10,471,160 (the “160 Patent”)
2078	Benešová, M, <i>et al.</i> , Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer, <i>J Nucl Med.</i> 2015; 56:914–920

Exhibit No.	Description
2079	U.S. Patent No. 10,398,791
2080	Deposition Testimony of Dr. Rebecca Abergel, Ph.D.
2094	Google data for Kratochwil, et al, 225Ac-PSMA-617 for PSMA-targeted α -radiation therapy of metastatic castration-resistant prostate cancer, https://scholar.google.com/scholar?hl=en&as_sdt=0%2C34&q=225+Ac-PSMA-617+for+PSMA-Targeted+%CE%B1-+Radiation+Therapy+of+Metastatic+Castration-Resistant+Prostate+Cancer&btnG= (last visited 10/21/2025)
2095	Altmetric data for Kratochwil, et al, 225Ac-PSMA-617 for PSMA-targeted α -radiation therapy of metastatic castration-resistant prostate cancer, https://www.altmetric.com/details/9534712#score (last visited 10/21/2025)
2097	Kratochwil, C, <i>et al.</i> , Targeted α -Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵ Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control, <i>J Nucl Med.</i> 2018 May;59(5):795-802.
2098	Sathekge, M, <i>et al.</i> , Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving ²²⁵ Ac-PSMA-617 Radioligand Therapy, <i>J Nucl Med.</i> 2020 Jan;61(1):62-69.
2099	Rathke, H, <i>et al.</i> , First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT, <i>European Journal of Nuclear Medicine and Molecular Imaging</i> (2021) 48:311–312.
2100	Kratochwil, C, <i>et al.</i> , Patients Resistant Against PSMA-Targeting α -Radiation Therapy Often Harbor Mutations in DNA Damage-Repair–Associated Genes, <i>J Nucl Med.</i> 2020; 61:683–688
2101	Kratochwil, C, <i>et al.</i> , Targeted α -Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵ Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding, <i>J Nucl Med.</i> 2017 Oct;58(10):1624-1631. (“Kratochwil 2017”)

Exhibit No.	Description
2102	van der Doelen, MJ, <i>et al.</i> , Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy, <i>Urologic Oncology</i> (2021) 39:729.e7–729.e16
2108	Feng, Y., et. al. A Third Generation PSMA-targeted Agent [211At]YF2: Synthesis and In Vivo Evaluation, <i>Nucl. Med. Biol.</i> 2024:134-135 (“Feng”)
2110	Cimons et al., “Cancer Drugs Face Long Road From Mice to Men,” Los Angeles Times, https://www.latimes.com/archives/la-xpm-1998-may-06-mn-46795-story.html (1998).
2111	Denison, TA et al, Tumor Heterogeneity and its Implication to Drug Delivery, <i>J Control Release</i> 2012 December 10; 164(2): 187-191.doi:10.1016/j.jconrel.2012.04.014. (“Denison”)
2112	Turner, PG, et al. ²²³ Ra and other bone-targeting radiopharmaceuticals—the translation of radiation biology into clinical practice. <i>Fr. J. Radiol</i> 2015;88:20140752 at 5. (“Turner”)
2113	Abou, DS, <i>et al.</i> , Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis, <i>J Natl Cancer Inst</i> 2016; 108(5): djv380
2114	DeBlonde, GJ, Abergel, RJ, “Active Actinium,” <i>Nat Chem.</i> , vol. 8, no. 11, pg. 1084 (November 2016) (“Abergel 2016”)
2115	Pallares RM and Abergel RJ, Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand? <i>Front. Med.</i> 2022; 9:1020188 (“Abergel 2022”)
2116	Burnett, AK, et al, A Comparison of Low Dose Cytarabine and Hydroxyurea With or Without All trans Retinoic Acid for Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome in Patients Not Considered Fit for Intensive Treatment, <i>Cancer</i> 2007; 109:1114-24 (“Burnett”)
2117	Winter, JN, et al., Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. <i>Cancer</i> 1985; 56(3):443-9 (“Winter”)

Exhibit No.	Description
2118	Tilly, H, et al., Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients, <i>Cancer</i> 1985; 55(8):1633-6 (“Tilly”)
2119	Cheson, BD, et al., A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes, <i>J Clin Oncol</i> 1986; 4(12):1857-64 (“Cheson”)
2120	Lin M, et al., Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives, <i>Cancer Biother Radiopharm</i> 2021 Apr;36(3):237-251 (“Lin”)
2121	Morton, JJ, et al. Humanized mouse xenograft models: narrowing the tumor-microenvironment gap, <i>Cancer Res.</i> 2016; 76(21): 6153–6158 (“Morton”)
2122	Zacherl, MT, et al., First Clinical Results for PSMA-Targeted α -Therapy Using ^{225}Ac -PSMA-I&T in Advanced-mCRPC Patients, <i>J. Nucl. Med.</i> 2021; 62:669-674 (“Zacherl”)
2123	Fanti, S, et al. Highlights of the 30th Annual Congress of the EANM, Vienna 2017: “Yes we can – make nuclear medicine great again,” <i>Eur. J. Nuc. Med. Mol. Im.</i> 2018; 45:1781–1794 (“Fanti”)
2124	https://www.eanm.org/congresses-events/awards-grants/winners/
2125	Nonnekens, J., et al., ^{213}Bi -Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-StrandBreaks in Prostate Cancer Xenografts, <i>Canc. Bioth. Rad.</i> 2017, 32 (2), 67-73 (“Nonnekens”)
2126	Alam, MR, et al., A Review of ^{177}Lu -PSMA and ^{225}Ac -PSMA as Emerging Theranostic Agents in Prostate Cancer, <i>Cureus</i> 2022; 14(9): e29369 (“Alam”)
2127	Feuerecker, B., et al., Clinical Translation of Targeted α -Therapy: An Evolution or a Revolution? <i>J Nucl Med</i> 2023; 64:685–692 (“Feuerecker”)
2128	Lepareur, N. An overview of current phase 3 radiopharmaceutical therapy clinical trials <i>Front. Med.</i> 2025 12:1549676. (“Lepareur”)

Exhibit No.	Description
2129	Jalloul, W., <i>et al.</i> Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management <i>Pharmaceuticals</i> 2025 , 18, 1215 (“Jalloul”)
2130	Munekane, M, et. al., Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics, <i>Anal. Sci.</i> 2024 40:803-826. (“Munekane”)
2131	PubMed results: Ex. 1045 Kratochwil 2016 last visited October 21, 2025
2132	PubMed results: Ex. 1028: Weineisen 2015 last visited October 21, 2025
2133	Google Scholar results: Ex. 1028: Weineisen 2015 last visited October 21, 2025
2134	Zalutsky, MR and Pruszyński, M, Astatine-211: production and availability. <i>Current radiopharmaceuticals</i> 2011;4(3):177-185.
2135	Nordstrom, M. <i>et al</i> , Identification of plasma protein profiles associated with risk groups of prostate cancer patients, <i>Proteomics Clin. Appl.</i> 2014 December; 8(0): 951-962 (“Nordstrom”)
2136	Afshar-Oromieh, A., <i>et al</i> , The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer, <i>J. Nucl. Med.</i> 2016; 57:79S-89S, DOI: 10.2967/jnumed.115.170720 (“Afshar-Oromieh”)
2137	Berney, DM <i>et al</i> , Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome, <i>British Journal of Cancer</i> (2016) 114, 1078-1083, doi: 10.1038/bjc.2016.86 (“Berney”)
2139	Deposition testimony of Dr. Michael Zalutsky
2140	Rowe, SP, <i>et al</i> , Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer, <i>J. Nucl. Med.</i> 2016; 57:90S-96S, DOI: 10.2967/jnumed.115.170175 (“Rowe”)

Exhibit No.	Description
2141	National Center for Biotechnology Information. PubChem Compound Summary for CID 156596528, Zadavotide guraxetan. https://pubchem.ncbi.nlm.nih.gov/compound/156596528#section=2D-Structure . Accessed Aug. 15, 2026.
2142	National Center for Biotechnology Information. PubChem Compound Summary for CID 158782, https://pubchem.ncbi.nlm.nih.gov/compound/158782 . Accessed Aug. 15, 2026.
2143	Boy, C. <i>et al</i> , ⁶⁸ Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax, <i>Eur. J. Nucl. Med. Mol. Imaging</i> (2011) 38:1224-1236, DOI 10.1007/s00259-011-1760-x (“Boy”)
2144	Obata, H. <i>et al</i> , DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy, <i>Pharmaceutics</i> , 2023, 15, 1926 https://doi.org/10.3390/pharmaceutics15071926 (“Zalutsky 2023”)
2145	Huynh, TT , <i>et al</i> , Enhancing the Therapeutic Index of [²¹¹ At]YF2 with Iodo Pseudo Carrier: A Simple Strategy for Reducing Accumulation in Kidneys, Salivary and Lacrimal glands, <i>Nucl Med Biol.</i> 2025; 146-147: 109028 doi:10.1016/j.nucmedbio.2025.109028
2146	Vaidyanathan, G. and Zalutsky, M.R., Applications of ²¹¹ At and ²²³ Ra in Targeted Alpha-Particle Radiotherapy, <i>Curr Radiopharm</i> , 2011 October; 4(4): 283-294
2147	Mease, RC, <i>et al</i> , An Improved ²¹¹ At-Labeled Agent for PSMA-Targeted α-Therapy, <i>J Nucl Med</i> 2022; 63-259-267, DOI: 10.2967/jnumed.121.262098 (“Zalutsky 2022”)
2148	Zalutsky, M.R. and Pruszynski, M., Astatine-211: Production and Availability, <i>Curr Radiopharm.</i> 2011 July; 4(3): 177-185 (“Zalutsky 2011”)

Exhibit No.	Description
2149	Maguire, W.F., <i>et al</i> , Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with ²²⁵ Ac for α-Particle Radioimmunotherapy of Cancer, <i>J Nucl Med</i> , 2014; 55(9):1492-1498, DOI: 10.2967/jnumed.114.138347
2153	Vaidyanathan, G., <i>et al</i> , Synthesis and Preliminary Evaluation of ²¹¹ At-labeled Inhibitors of Prostate-Specific Membrane Antigen for Targeted Alpha Particle Therapy of Prostate Cancer, <i>Nucl Med Biol</i> . 2021; 94-95: 67-80. doi:10.1016/j.nucmedbio.2021.01.002.
2155	Kratochwil, C., et al. ²¹³ Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience, <i>Eur. J. Nucl. Med. Mol. Imaging</i> , 2014; 41:2106–2119
2156	Michael Gorin CV
2158	Kiess, et al. (2S)-2-(3-(1-Carboxy-5-(4- ²¹¹ At-Astatobenzamido)Pentyl) Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle, <i>J Nucl Med</i> 2016; 57:1569–1575
2159	Vallabhajosula et al., Prediction of Myelotoxicity Based on Bone Marrow Radiation-Absorbed Dose: Radioimmunotherapy Studies Using ⁹⁰ Y- and ¹⁷⁷ Lu-Labeled J591 Antibodies Specific for Prostate-Specific Membrane Antigen, <i>J. Nucl. Med.</i> , Vol, 46, No. 5, pgs. 850-858 (2005)
2160	Cloutier, et al., MIRD Pamphlet No. 21, Dose Estimate Report No. 2, “Summary of Current Radiation Dose Estimates to Humans from ⁶⁶ Ga-, ⁶⁷ Ga-, ⁶⁸ Ga-, and ⁷² Ga-citrate,” <i>J. Nucl. Med.</i> , vol. 14, no. 10, pgs. 755-756 (1973).
2161	Jaggi, SJ, et al. Efforts to Control the Errant Products of a Targeted In vivo Generator, <i>Cancer Res</i> . 2005; 65: (11)
2162	Forrer, F, et al., Treatment with ¹⁷⁷ Lu-DOTATOC of Patients with Relapse of Neuroendocrine Tumors After treatment with ⁹⁰ Y-DOTATOC, <i>J Nucl Med</i> . 2005; 46:1310–1316
2163	Dorso, L, et al., Long-Term Toxicity of ²¹³ Bi-Labelled BSA in Mice, <i>PLOS ONE</i> 2016; 11(3), e0151330

Exhibit No.	Description
2164	Common Terminology Criteria for Adverse Events (CTCAE), V. 5.0, November 27, 2017, U.S. Dept. Health & Human Services.
2165	Sathekge, M. , et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study <i>Lanc. Onc.</i> , 25 (2), 2024, p. 175-183.
2166	Ex. 1027: Weineisen 2014 Pubmed
2167	Ex. 1027: Weineisen 2014 Google
2168	Ex. 1006: Chatalic Google
2169	Ex. 1015: Miederer Pubmed
2170	Ex. 1015: Miederer Google
2171	Ex. 1011: Jurcic Google
2172	Ex. 1031: Kratochwil Google
2173	Afshar-Oromieh et al., The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions, <i>J. Nucl. Med.</i> , vol. 56, no. 11, 1697-1705 (2015).
2174	Schwartz et al., Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody, <i>Phys. Med. Biol.</i> Vol. 56, no. 3, pgs. 721-733 (2011).
2175	Tagawa ST, et al., Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer, <i>Cancer</i> 2010, 116(4 Suppl):1075-83.

Exhibit No.	Description
2176	Tagawa ST, et al., Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody J591 in men with metastatic castration-resistant prostate cancer, <i>Front Oncol</i> 2013, 26:3:214
2177	Tagawa ST, et al., Prostate-Specific Membrane Antigen- Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591, <i>J Clin Oncol</i> 2023, 3:JCO2300573
2178	Zalutsky et al., Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6, <i>J. Nucl. Med.</i> Vol. 49, no. 1, pgs. 30-38 (2008)
2179	Abbas et al., Experimental α -particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl- DOTA-trastuzumab, <i>EJNMMI Res.</i> Vol. 1, no. 1, pg.18 (2011)
2180	Parker et al., Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, <i>N. Engl. J. Med.</i> Vol 369, no. 3, pgs. 213-223
2181	Meredith et al., Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab, <i>J. Nucl. Med.</i> , vol. 55, no. 10, pgs. 1636-1642 (2014)
2182	Cordier et al., Targeted alpha- radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA- [Thi8,Met(O2)11]-substance P: a pilot trial, <i>Eur. J. Nucl. Med. Mol. Imaging</i> , vol. 37, no. 7, pgs. 1335-1344 (2010)
2183	Müller et al., A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α - and β - radionuclide therapy: an in vivo proof-of- concept study with a new receptor-targeted folate derivative, <i>J. Nucl. Med.</i> , vol. 53, no. 12, pgs. 1951-1959 (2012).

Exhibit No.	Description
2184	Pimm et al, Blood and tissue kinetics of radiolabelled anti-CEA monoclonal antibody and F(ab)2 and Fab fragments in nude mice with human tumour xenografts: implications for tumour imaging and radioimmunotherapy, <i>Nucl. Med. Commun.</i> , vol. 10, no. 8, pgs. 585-593 (1989)
2185	Sathekge, M., et al., 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study, <i>Eur J Nucl Med Mol Imaging</i> 2019, 46:129–138
2186	Alan-Selcuk, N. <i>et al.</i> , Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer, <i>J Nucl Med</i> 2023 Oct;64(10):1574-1580
2187	Kauffman, N. <i>et al.</i> , Intra-Arterial Delivery of Radiopharmaceuticals in Oncology: Current Trends and the Future of Alpha-Particle Therapeutics, <i>Pharmaceutics</i> 2023 Apr; 15(4):1138
2188	Okamoto, S. <i>et al.</i> , Clinical Perspectives of Theranostics, <i>Molecules</i> 2021 Apr; 26(8):2232
2189	Oyen, W.J. and de Bono, J.S., Targeted α -Based Treatment of Metastatic Castration-Resistant Prostate Cancer: Revolutionizing Systemic Radiotherapy?, <i>J Nucl Med</i> 2016 Dec; 57(12): 1838-1839